{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T03:04:52Z","timestamp":1793156692822,"version":"4.5.0"},"reference-count":214,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,29]],"date-time":"2025-01-29T00:00:00Z","timestamp":1738108800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["K 12 HD105271"],"award-info":[{"award-number":["K 12 HD105271"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005347","name":"American Association for the Study of Liver Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005347","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Obesity Pillars"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.obpill.2025.100164","type":"journal-article","created":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T02:40:16Z","timestamp":1738377616000},"page":"100164","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":51,"special_numbering":"C","title":["Metabolic dysfunction-associated steatotic liver disease (MASLD) in children with obesity: An Obesity Medicine Association (OMA) and expert joint perspective 2025"],"prefix":"10.1016","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-5220-668X","authenticated-orcid":false,"given":"Jennifer","family":"Panganiban","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohit","family":"Kehar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samar H.","family":"Ibrahim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phillipp","family":"Hartmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3348-7762","authenticated-orcid":false,"given":"Shilpa","family":"Sood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Hassan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charina M","family":"Ramirez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohit","family":"Kohli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marisa","family":"Censani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin","family":"Mauney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0207-7864","authenticated-orcid":false,"given":"Suzanne","family":"Cuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0534-4254","authenticated-orcid":false,"given":"Sara","family":"Karjoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.obpill.2025.100164_bib1","unstructured":"Hampl SE, Hassink SG, Skinner AC, et\u00a0al. CLINICAL PRACTICE GUIDELINE guidance for the clinician in rendering pediatric care clinical practice guideline for the evaluation and treatment of children and adolescents with obesity. . ."},{"key":"10.1016\/j.obpill.2025.100164_bib2","doi-asserted-by":"crossref","DOI":"10.2337\/dc24-1236","article-title":"Steatotic liver disease in pediatric obesity and increased risk for youth-onset type 2 diabetes","author":"Putri","year":"2024","journal-title":"Diabetes Care"},{"issue":"3","key":"10.1016\/j.obpill.2025.100164_bib3","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1002\/jpn3.12236","article-title":"Utilization and perspectives of weight loss medications in pediatric metabolic dysfunction-associated steatotic liver disease","volume":"79","author":"Kehar","year":"2024","journal-title":"J\u00a0Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.obpill.2025.100164_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.obpill.2022.100027","article-title":"Nonalcoholic fatty liver disease and obesity: an obesity medicine association (OMA) clinical practice statement (CPS) 2022","volume":"3","author":"Karjoo","year":"2022","journal-title":"Obesity Pillars"},{"key":"10.1016\/j.obpill.2025.100164_bib5","series-title":"A\u00a0multisociety delphi consensus statement on new fatty liver disease nomenclature","author":"Rinella","year":"2023"},{"issue":"5","key":"10.1016\/j.obpill.2025.100164_bib6","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1097\/HEP.0000000000000323","article-title":"AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease","volume":"77","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.obpill.2025.100164_bib7","first-page":"196","article-title":"Epidemiology of pediatric nonalcoholic fatty liver disease","volume":"17","author":"Yu","year":"2021"},{"issue":"4","key":"10.1016\/j.obpill.2025.100164_bib8","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1542\/peds.2006-1212","article-title":"Prevalence of fatty liver in children and adolescents","volume":"118","author":"Schwimmer","year":"2006","journal-title":"Pediatrics"},{"issue":"3","key":"10.1016\/j.obpill.2025.100164_bib9","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.jpeds.2012.08.043","article-title":"Increasing prevalence of nonalcoholic fatty liver disease among United States adolescents, 1988-1994 to 2007-2010","volume":"162","author":"Welsh","year":"2014","journal-title":"J\u00a0Pediatr"},{"key":"10.1016\/j.obpill.2025.100164_bib10","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.jpeds.2018.04.047","article-title":"Pediatric nonalcoholic fatty liver disease in new york city: an autopsy study","volume":"200","author":"Fernandes","year":"2018","journal-title":"J\u00a0Pediatr"},{"issue":"3","key":"10.1016\/j.obpill.2025.100164_bib11","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1053\/j.sempedsurg.2009.04.004","article-title":"Diagnosis and treatment of pediatric nonalcoholic steatohepatitis and the implications for bariatric surgery","volume":"18","author":"Pardee","year":"2010","journal-title":"Semin Pediatr Surg"},{"issue":"8","key":"10.1016\/j.obpill.2025.100164_bib12","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1053\/j.gastro.2016.03.009","article-title":"Comparison of the phenotype and approach to pediatric vs adult patients with nonalcoholic fatty liver disease","volume":"150","author":"Nobili","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.obpill.2025.100164_bib13","unstructured":"Phen C, Ramirez CM. Hepatic steatosis in the pediatric population: an overview of pathophysiology, genetics, and diagnostic workup."},{"issue":"36","key":"10.1016\/j.obpill.2025.100164_bib14","article-title":"Pediatric non-alcoholic fatty liver disease: recent solutions, unresolved issues, and future research directions","volume":"22","author":"Clemente","year":"2016","journal-title":"WJG"},{"issue":"1","key":"10.1016\/j.obpill.2025.100164_bib15","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.cld.2017.08.002","article-title":"The genetics of pediatric nonalcoholic fatty liver disease","volume":"22","author":"Goyal","year":"2018","journal-title":"Clin Liver Dis"},{"key":"10.1016\/j.obpill.2025.100164_bib16","article-title":"Interplay between gut microbiome, host genetic and epigenetic modifications in MASLD and MASLD-related hepatocellular carcinoma","author":"Ha","year":"2024","journal-title":"Gut"},{"key":"10.1016\/j.obpill.2025.100164_bib17","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.coemr.2021.05.003","article-title":"Pediatric nonalcoholic fatty liver disease and the microbiome: mechanisms contributing to pathogenesis and progression","volume":"19","author":"Salzman","year":"2021","journal-title":"Curr. Opinion Endocrine Metabol. Res."},{"issue":"11","key":"10.1016\/j.obpill.2025.100164_bib18","doi-asserted-by":"crossref","first-page":"3496","DOI":"10.1210\/clinem\/dgaa574","article-title":"Sex hormone relations to histologic severity of pediatric nonalcoholic fatty liver disease","volume":"105","author":"Mueller","year":"2020","journal-title":"J\u00a0Clin Endocrinol Metabol"},{"key":"10.1016\/j.obpill.2025.100164_bib19","unstructured":"Jaruvongvanich V, Sanguankeo A, Riangwiwat T, Upala S. Testosterone, sex hormone-binding globulin and nonalcoholic fatty liver disease: a systematic review and meta-analysis. . .doi: 10.5604\/16652681.1235481."},{"issue":"3","key":"10.1016\/j.obpill.2025.100164_bib20","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1097\/MPG.0000000000002527","article-title":"Community socioeconomic deprivation and nonalcoholic fatty liver disease severity","volume":"70","author":"Orkin","year":"2020","journal-title":"J\u00a0Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.obpill.2025.100164_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpeds.2023.113818","article-title":"Food insecurity and pediatric nonalcoholic fatty liver disease severity","volume":"265","author":"Orkin","year":"2024","journal-title":"J\u00a0Pediatr"},{"issue":"5","key":"10.1016\/j.obpill.2025.100164_bib22","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1053\/j.gastro.2020.07.034","article-title":"Progression of fatty liver disease in children receiving standard of care lifestyle advice","volume":"159","author":"Xanthakos","year":"2020","journal-title":"Gastroenterology"},{"issue":"9","key":"10.1016\/j.obpill.2025.100164_bib23","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1016\/j.transproceed.2023.08.020","article-title":"Liver transplant outcomes in young adults with cirrhosis related to nonalcoholic fatty liver disease","volume":"55","author":"Bezinover","year":"2023","journal-title":"Transplant Proc"},{"issue":"5","key":"10.1016\/j.obpill.2025.100164_bib24","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1016\/j.jhep.2021.06.034","article-title":"Non-alcoholic fatty liver disease in children and young adults is associated with increased long-term mortality","volume":"75","author":"Simon","year":"2021","journal-title":"J\u00a0Hepatol"},{"issue":"1","key":"10.1016\/j.obpill.2025.100164_bib25","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1002\/j.1536-4801.2006.tb00012.x","article-title":"Relationship of hepatic steatosis to adipose tissue distribution in pediatric nonalcoholic fatty liver disease","volume":"42","author":"Fishbein","year":"2006","journal-title":"J\u00a0Pediatr Gastroenterol Nutr"},{"issue":"10","key":"10.1016\/j.obpill.2025.100164_bib26","doi-asserted-by":"crossref","first-page":"3872","DOI":"10.1210\/jc.2009-1125","article-title":"Gender-specific prevalences of fatty liver in obese children and adolescents: roles of body fat distribution, sex steroids, and insulin resistance","volume":"94","author":"Denzer","year":"2009","journal-title":"J\u00a0Clin Endocrinol Metabol"},{"issue":"2","key":"10.1016\/j.obpill.2025.100164_bib27","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.dld.2007.09.009","article-title":"Relationship between nonalcoholic fatty liver disease prevalence and visceral fat in obese adolescents","volume":"40","author":"D\u00e2maso","year":"2007","journal-title":"Dig Liver Dis"},{"issue":"3","key":"10.1016\/j.obpill.2025.100164_bib28","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1056\/NEJMra1514009","article-title":"Mechanisms, pathophysiology, and management of obesity","volume":"376","author":"Heymsfield","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"7121","key":"10.1016\/j.obpill.2025.100164_bib29","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1038\/nature05482","article-title":"Mechanisms linking obesity to insulin resistance and type 2 diabetes","volume":"444","author":"Kahn","year":"2006","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.obpill.2025.100164_bib30","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1172\/JCI23621","article-title":"Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease","volume":"115","author":"Donnelly","year":"2005","journal-title":"J\u00a0Clin Investig"},{"issue":"10","key":"10.1016\/j.obpill.2025.100164_bib31","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1172\/JCI0215001","article-title":"Leptin reverses insulin resistance and hepatic steatosis in patients with severe lipodystrophy","volume":"109","author":"Petersen","year":"2002","journal-title":"J\u00a0Clin Investig"},{"key":"10.1016\/j.obpill.2025.100164_bib32","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1056\/NEJM199602013340503","article-title":"Serum immunoreactive-leptin concentrations in normal-weight and obese humans","volume":"334","author":"Considine","year":"1996","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"10.1016\/j.obpill.2025.100164_bib33","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines9070762","article-title":"Role of leptin in non-alcoholic fatty liver disease","volume":"9","author":"Jim\u00e9nez-Cortegana","year":"2021","journal-title":"Biomedicines"},{"issue":"2","key":"10.1016\/j.obpill.2025.100164_bib34","doi-asserted-by":"crossref","first-page":"547","DOI":"10.2337\/diacare.27.2.547","article-title":"Adiponectin in youth: relationship to visceral adiposity, insulin sensitivity, and beta-cell function","volume":"27","author":"Bacha","year":"2004","journal-title":"Diabetes Care"},{"issue":"5","key":"10.1016\/j.obpill.2025.100164_bib35","doi-asserted-by":"crossref","first-page":"737","DOI":"10.2217\/bmm.13.13","article-title":"Serum adiponectin, leptin, resistin and RBP4 levels in obese and metabolic syndrome children with nonalcoholic fatty liver disease","volume":"7","author":"Boyraz","year":"2013","journal-title":"Biomarkers Med"},{"issue":"5","key":"10.1016\/j.obpill.2025.100164_bib36","doi-asserted-by":"crossref","first-page":"609","DOI":"10.4254\/wjh.v15.i5.609","article-title":"Noninvasive biomarkers in pediatric nonalcoholic fatty liver disease","volume":"15","author":"Jayasekera","year":"2023","journal-title":"World J Hepatol"},{"issue":"1","key":"10.1016\/j.obpill.2025.100164_bib37","doi-asserted-by":"crossref","DOI":"10.1186\/s12967-023-04770-8","article-title":"The potential role of omentin-1 in obesity-related metabolic dysfunction-associated steatotic liver disease: evidence from translational studies","volume":"21","author":"Salvoza","year":"2023","journal-title":"J\u00a0Transl Med"},{"issue":"3","key":"10.1016\/j.obpill.2025.100164_bib38","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.jhep.2013.04.013","article-title":"Community-based lifestyle modification programme for non-alcoholic fatty liver disease: a randomized controlled trial","volume":"59","author":"Wong","year":"2013","journal-title":"J\u00a0Hepatol"},{"issue":"2","key":"10.1016\/j.obpill.2025.100164_bib39","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1053\/j.gastro.2015.04.005","article-title":"Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis","volume":"149","author":"Vilar-Gomez","year":"2015","journal-title":"Gastroenterology"},{"issue":"10","key":"10.1016\/j.obpill.2025.100164_bib40","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1016\/j.cgh.2021.11.039","article-title":"Intensive lifestyle management improves steatosis and fibrosis in pediatric nonalcoholic fatty liver disease","volume":"20","author":"Lefere","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.obpill.2025.100164_bib41","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1097\/MCG.0b013e3181dd1348","article-title":"Generalizability of the nonalcoholic steatohepatitis clinical research network histologic scoring system for nonalcoholic fatty liver disease","volume":"45","author":"Juluri","year":"2012","journal-title":"J\u00a0Clin Gastroenterol"},{"key":"10.1016\/j.obpill.2025.100164_bib42","series-title":"Bright futures: guidelines for health supervision of infants, children and adolescents, 4th edition","first-page":"1","author":"Joseph","year":"2017"},{"issue":"4","key":"10.1016\/j.obpill.2025.100164_bib43","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1097\/MCG.0000000000000925","article-title":"Nonalcoholic steatohepatitis is the most rapidly increasing indication for liver transplantation in young adults in the United States","volume":"52","author":"Doycheva","year":"2018","journal-title":"J\u00a0Clin Gastroenterol"},{"issue":"7","key":"10.1016\/j.obpill.2025.100164_bib44","first-page":"407","article-title":"Overview of updated practice guidelines for pediatric nonalcoholic fatty liver disease","volume":"14","author":"Shah","year":"2018"},{"issue":"2","key":"10.1016\/j.obpill.2025.100164_bib45","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1097\/MPG.0b013e31821b4b61","article-title":"Ultrasonographic quantitative estimation of hepatic steatosis in children with NAFLD","volume":"53","author":"Shannon","year":"2011","journal-title":"J\u00a0Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.obpill.2025.100164_bib46","article-title":"Transient elastography in the diagnosis of pediatric non-alcoholic fatty liver disease and its subtypes","volume":"10","author":"Yang","year":"2022","journal-title":"Front Pediatr"},{"key":"10.1016\/j.obpill.2025.100164_bib47","doi-asserted-by":"crossref","DOI":"10.3389\/fped.2021.784221","article-title":"Magnetic resonance imaging-proton density fat fraction vs. transient elastography-controlled attenuation parameter in diagnosing non-alcoholic fatty liver disease in children and adolescents: a meta-analysis of diagnostic accuracy","volume":"9","author":"Jia","year":"2022","journal-title":"Front Pediatr"},{"issue":"1","key":"10.1016\/j.obpill.2025.100164_bib48","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.jpeds.2013.07.050","article-title":"Use of magnetic resonance elastography to assess hepatic fibrosis in children with chronic liver disease","volume":"164","author":"Xanthakos","year":"2015","journal-title":"J\u00a0Pediatr"},{"issue":"2","key":"10.1016\/j.obpill.2025.100164_bib49","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1097\/MPG.0000000000001482","article-title":"NASPGHAN clinical practice guideline for the diagnosis and treatment of nonalcoholic fatty liver disease in children","volume":"64","author":"Vos","year":"2017","journal-title":"J\u00a0Pediatr Gastroenterol Nutr"},{"issue":"10","key":"10.1016\/j.obpill.2025.100164_bib50","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1111\/apt.12518","article-title":"Paediatric gastroenterology evaluation of overweight and obese children referred from primary care for suspected non\u2010alcoholic fatty liver disease","volume":"38","author":"Schwimmer","year":"2013","journal-title":"Aliment Pharmacol Ther"},{"issue":"4","key":"10.1016\/j.obpill.2025.100164_bib51","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1053\/j.gastro.2009.12.052","article-title":"SAFETY study: alanine aminotransferase cutoff values are set too high for reliable detection of pediatric chronic liver disease","volume":"138","author":"Schwimmer","year":"2010","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.obpill.2025.100164_bib52","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1002\/hep.31317","article-title":"Alanine aminotransferase and gamma-glutamyl transpeptidase predict histologic improvement in pediatric nonalcoholic steatohepatitis","volume":"73","author":"Newton","year":"2021","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.obpill.2025.100164_bib53","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/j.cgh.2013.09.050","article-title":"Evidence and recommendations for imaging liver fat in children, based on systematic review","volume":"12","author":"Awai","year":"1982","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.obpill.2025.100164_bib54","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the american association for the study of liver diseases","volume":"67","author":"Chalasani","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.obpill.2025.100164_bib55","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2022\/8435581","article-title":"Screening patterns of nonalcoholic fatty liver disease in children with obesity in canadian primary care: a cross-sectional study","volume":"2022","author":"Morkem","year":"2022","journal-title":"Canadian J Gastroenterol Hepatol"},{"issue":"5","key":"10.1016\/j.obpill.2025.100164_bib56","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1002\/hep.28785","article-title":"The economic and clinical burden of nonalcoholic fatty liver disease in the United States and europe","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology"},{"issue":"8","key":"10.1016\/j.obpill.2025.100164_bib57","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1007\/s40273-022-01140-y","article-title":"The economic burden of non-alcoholic steatohepatitis: a systematic review","volume":"40","author":"Witkowski","year":"2022","journal-title":"Pharmacoeconomics"},{"issue":"4","key":"10.1016\/j.obpill.2025.100164_bib58","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1016\/j.advnut.2023.04.011","article-title":"Mediterranean diet-based interventions to improve anthropometric and obesity indicators in children and adolescents: a systematic review with meta-analysis of randomized controlled trials","volume":"14","author":"L\u00f3pez-Gil","year":"2023","journal-title":"Adv Nutr"},{"issue":"20","key":"10.1016\/j.obpill.2025.100164_bib59","doi-asserted-by":"crossref","DOI":"10.3390\/ijerph192013040","article-title":"Mediterranean diet versus very low-calorie ketogenic diet: effects of reaching 5% body weight loss on body composition in subjects with overweight and with obesity-A cohort study","volume":"19","author":"Di Rosa","year":"2022","journal-title":"Int J Environ Res Publ Health"},{"issue":"4","key":"10.1016\/j.obpill.2025.100164_bib60","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.amjmed.2015.11.028","article-title":"Systematic review of the mediterranean diet for long-term weight loss","volume":"129","author":"Mancini","year":"2016","journal-title":"Am J Med"},{"key":"10.1016\/j.obpill.2025.100164_bib61","doi-asserted-by":"crossref","DOI":"10.1016\/j.obpill.2023.100087","article-title":"Obesity and malnutrition in children and adults: a clinical review","volume":"8","author":"Bradley","year":"2023","journal-title":"Obesity Pillars"},{"issue":"3","key":"10.1016\/j.obpill.2025.100164_bib62","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.cmet.2018.01.005","article-title":"An integrated understanding of the rapid metabolic benefits of a carbohydrate-restricted diet on hepatic steatosis in humans","volume":"27","author":"Mardinoglu","year":"2018","journal-title":"Cell Metab"},{"issue":"5","key":"10.1016\/j.obpill.2025.100164_bib63","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.3945\/ajcn.110.007674","article-title":"Short-term weight loss and hepatic triglyceride reduction: evidence of a metabolic advantage with dietary carbohydrate restriction","volume":"93","author":"Browning","year":"2011","journal-title":"Am J Clin Nutr"},{"issue":"10","key":"10.1016\/j.obpill.2025.100164_bib64","doi-asserted-by":"crossref","DOI":"10.3390\/nu11102543","article-title":"The metabolic and hepatic impact of two personalized dietary strategies in subjects with obesity and nonalcoholic fatty liver disease: the fatty liver in obesity (FLiO) randomized controlled trial","volume":"11","author":"Marin-Alejandre","year":"2019","journal-title":"Nutrients"},{"issue":"3","key":"10.1016\/j.obpill.2025.100164_bib65","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1001\/jama.2018.20579","article-title":"Effect of a low free sugar diet vs usual diet on nonalcoholic fatty liver disease in adolescent boys: a randomized clinical trial","volume":"321","author":"Schwimmer","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.obpill.2025.100164_bib66","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/s12986-020-00481-9","article-title":"Effects of weight loss during a very low carbohydrate diet on specific adipose tissue depots and insulin sensitivity in older adults with obesity: a randomized clinical trial","volume":"17","author":"Goss","year":"2020","journal-title":"Nutr Metabol"},{"issue":"5","key":"10.1016\/j.obpill.2025.100164_bib67","article-title":"Lysosomal acid lipase as a molecular target of the very low carbohydrate ketogenic diet in morbidly obese patients: the potential effects on liver steatosis and cardiovascular risk factors","volume":"8","author":"Ministrini","year":"2019","journal-title":"J\u00a0Clin Med"},{"issue":"9","key":"10.1016\/j.obpill.2025.100164_bib68","article-title":"Very low-carbohydrate ketogenic diet for the treatment of severe obesity and associated non-alcoholic fatty liver disease: the role of sex differences","volume":"12","author":"D'Abbondanza","year":"2020","journal-title":"Nutrients"},{"issue":"2","key":"10.1016\/j.obpill.2025.100164_bib69","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1210\/jc.2016-2385","article-title":"Body composition changes after very-low-calorie ketogenic diet in obesity evaluated by 3 standardized methods","volume":"102","author":"Gomez-Arbelaez","year":"2017","journal-title":"J\u00a0Clin Endocrinol Metabol"},{"issue":"7\u20138","key":"10.1016\/j.obpill.2025.100164_bib70","first-page":"697","article-title":"Metabolic impact of a ketogenic diet compared to a hypocaloric diet in obese children and adolescents","volume":"25","author":"Partsalaki","year":"2012","journal-title":"J\u00a0Pediatr Endocrinol Metabol"},{"issue":"10","key":"10.1016\/j.obpill.2025.100164_bib71","doi-asserted-by":"crossref","first-page":"769","DOI":"10.7326\/0003-4819-140-10-200405180-00006","article-title":"A\u00a0low-carbohydrate, ketogenic diet versus a low-fat diet to treat obesity and hyperlipidemia: a randomized, controlled trial","volume":"140","author":"Yancy","year":"2004","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.obpill.2025.100164_bib72","doi-asserted-by":"crossref","DOI":"10.1016\/j.obmed.2021.100353","article-title":"Effect of four week of 5:2 intermittent fasting on energy intake and body mass index among obese male students aged 18-25","volume":"25","author":"Fudla","year":"2021","journal-title":"Obesity Medicine"},{"key":"10.1016\/j.obpill.2025.100164_bib73","doi-asserted-by":"crossref","DOI":"10.3389\/fnut.2022.851054","article-title":"Exergaming during ramadan intermittent fasting improve body composition as well as physiological and psychological responses to physical exercise in adolescents with obesity","volume":"9","author":"Abedelmalek","year":"2022","journal-title":"Front Nutr"},{"issue":"11","key":"10.1016\/j.obpill.2025.100164_bib74","doi-asserted-by":"crossref","DOI":"10.3390\/nu13113697","article-title":"Time-limited eating and continuous glucose monitoring in adolescents with obesity: a pilot study","volume":"13","author":"Vidmar","year":"2021","journal-title":"Nutrients"},{"issue":"4","key":"10.1016\/j.obpill.2025.100164_bib75","doi-asserted-by":"crossref","DOI":"10.1111\/cob.12370","article-title":"Low-carbohydrate interventions for adolescent obesity: nutritional adequacy and guidance for clinical practice","volume":"10","author":"Jebeile","year":"2020","journal-title":"Clinical obesity"},{"issue":"5","key":"10.1016\/j.obpill.2025.100164_bib76","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1038\/ejcn.2016.268","article-title":"Nutritional adequacy of diets for adolescents with overweight and obesity: Considerations for dietetic practice","volume":"71","author":"Lister","year":"2017","journal-title":"Eur J Clin Nutr"},{"issue":"19","key":"10.1016\/j.obpill.2025.100164_bib77","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.3748\/wjg.v24.i19.2083","article-title":"Mediterranean diet and nonalcoholic fatty liver disease","volume":"24","author":"Anania","year":"2018","journal-title":"World J Gastroenterol"},{"issue":"12","key":"10.1016\/j.obpill.2025.100164_bib78","doi-asserted-by":"crossref","DOI":"10.3390\/nu11122971","article-title":"Mediterranean diet and NAFLD: what we know and questions that still need to be answered","volume":"11","author":"Plaz Torres","year":"2019","journal-title":"Nutrients"},{"issue":"3","key":"10.1016\/j.obpill.2025.100164_bib79","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1007\/s00394-023-03086-z","article-title":"Plant-based and vegetarian diets: an overview and definition of these dietary patterns","volume":"62","author":"Hargreaves","year":"2023","journal-title":"Eur J Nutr"},{"issue":"15","key":"10.1016\/j.obpill.2025.100164_bib80","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1056\/NEJMoa1203034","article-title":"A\u00a0trial of sugar-free or sugar-sweetened beverages and body weight in children","volume":"367","author":"de Ruyter","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"15","key":"10.1016\/j.obpill.2025.100164_bib81","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1056\/NEJMoa1203388","article-title":"A\u00a0randomized trial of sugar-sweetened beverages and adolescent body weight","volume":"367","author":"Ebbeling","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.obpill.2025.100164_bib82","doi-asserted-by":"crossref","first-page":"e220","DOI":"10.3928\/19382359-20190515-02","article-title":"Pediatric anti-inflammatory diet","volume":"48","author":"Mascarenhas","year":"2019","journal-title":"Pediatr Ann"},{"issue":"10","key":"10.1016\/j.obpill.2025.100164_bib83","article-title":"Does the mediterranean diet have any effect on lipid profile, central obesity and liver enzymes in non-alcoholic fatty liver disease (NAFLD) subjects? A systematic review and meta-analysis of randomized control trials","volume":"15","author":"Del Bo","year":"2023","journal-title":"Nutrients"},{"issue":"3","key":"10.1016\/j.obpill.2025.100164_bib84","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1080\/09637486.2021.1979478","article-title":"The effect of a mediterranean diet vs. a low-fat diet on non-alcoholic fatty liver disease in children: a randomized trial","volume":"73","author":"Akbulut","year":"2022","journal-title":"Int J Food Sci Nutr"},{"issue":"4","key":"10.1016\/j.obpill.2025.100164_bib85","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1016\/j.clnu.2018.08.010","article-title":"Higher adherence to plant-based diets are associated with lower likelihood of fatty liver","volume":"38","author":"Mazidi","year":"2019","journal-title":"Clin Nutr"},{"issue":"11","key":"10.1016\/j.obpill.2025.100164_bib86","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1007\/s10654-020-00627-2","article-title":"Adherence to a plant-based, high-fibre dietary pattern is related to regression of non-alcoholic fatty liver disease in an elderly population","volume":"35","author":"Alferink","year":"2020","journal-title":"Eur J Epidemiol"},{"issue":"11","key":"10.1016\/j.obpill.2025.100164_bib87","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1136\/gutjnl-2020-323106","article-title":"Effect of green-mediterranean diet on intrahepatic fat: the DIRECT PLUS randomised controlled trial","volume":"70","author":"Yaskolka","year":"2021","journal-title":"Gut"},{"key":"10.1016\/j.obpill.2025.100164_bib88","first-page":"1909","article-title":"Ketogenic diet and NAFLD: a great therapeutic 568 opportunity?","volume":"35","author":"Mancin","year":"2019","journal-title":"Acta Med Mediterr"},{"issue":"13","key":"10.1016\/j.obpill.2025.100164_bib89","doi-asserted-by":"crossref","first-page":"7347","DOI":"10.1073\/pnas.1922344117","article-title":"Effect of a ketogenic diet on hepatic steatosis and hepatic mitochondrial metabolism in nonalcoholic fatty liver disease","volume":"117","author":"Luukkonen","year":"2020","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.obpill.2025.100164_bib90","doi-asserted-by":"crossref","first-page":"607","DOI":"10.3389\/fendo.2020.00607","article-title":"Efficacy of a 2-month very low-calorie ketogenic diet (VLCKD) compared to a standard low-calorie diet in reducing visceral and liver fat accumulation in patients with obesity","volume":"11","author":"Cunha","year":"2020","journal-title":"Front Endocrinol"},{"issue":"20","key":"10.1016\/j.obpill.2025.100164_bib91","doi-asserted-by":"crossref","DOI":"10.3390\/nu15204468","article-title":"Effects of an eight week very low-calorie ketogenic diet (VLCKD) on white blood cell and platelet counts in relation to metabolic dysfunction-associated steatotic liver disease (MASLD) in subjects with overweight and obesity","volume":"15","author":"De Nucci","year":"2023","journal-title":"Nutrients"},{"issue":"6","key":"10.1016\/j.obpill.2025.100164_bib92","doi-asserted-by":"crossref","DOI":"10.3390\/nu16060874","article-title":"Higher-level steatosis is associated with a greater decrease in metabolic dysfunction-associated steatoic liver disease after eight weeks of a very low-calorie ketogenic diet (VLCKD) in subjects affected by overweight and obesity","volume":"16","author":"Sila","year":"2024","journal-title":"Nutrients"},{"issue":"1","key":"10.1016\/j.obpill.2025.100164_bib93","first-page":"26","article-title":"Ketogenic, hypocaloric diet improves nonalcoholic steatohepatitis","volume":"8","author":"Belopolsky","year":"2020","journal-title":"J\u00a0Translat Intern Med"},{"issue":"3","key":"10.1016\/j.obpill.2025.100164_bib94","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1089\/chi.2013.0022","article-title":"A\u00a0low-glycemic-load versus low-fat diet in the treatment of fatty liver in obese children","volume":"9","author":"Ramon-Krauel","year":"2013","journal-title":"Child Obes"},{"issue":"2","key":"10.1016\/j.obpill.2025.100164_bib95","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1002\/oby.22065","article-title":"Flipping the metabolic switch: understanding and applying the health benefits of fasting","volume":"26","author":"Anton","year":"2018","journal-title":"Obesity"},{"issue":"4","key":"10.1016\/j.obpill.2025.100164_bib96","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1210\/er.2017-00211","article-title":"Metabolic flexibility as an adaptation to energy resources and requirements in health and disease","volume":"39","author":"Smith","year":"2018","journal-title":"Endocr Rev"},{"issue":"6","key":"10.1016\/j.obpill.2025.100164_bib97","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1016\/j.cmet.2012.04.019","article-title":"Time-restricted feeding without reducing caloric intake prevents metabolic diseases in mice fed a high-fat diet","volume":"15","author":"Hatori","year":"2012","journal-title":"Cell Metab"},{"key":"10.1016\/j.obpill.2025.100164_bib98","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1146\/annurev-nutr-071816-064916","article-title":"\u0392-hydroxybutyrate: a signaling metabolite","volume":"37","author":"Newman","year":"2017","journal-title":"Annu Rev Nutr"},{"issue":"1","key":"10.1016\/j.obpill.2025.100164_bib99","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.cmet.2022.12.006","article-title":"Diurnal transcriptome landscape of a multi-tissue response to time-restricted feeding in mammals","volume":"35","author":"Deota","year":"2023","journal-title":"Cell Metab"},{"key":"10.1016\/j.obpill.2025.100164_bib100","doi-asserted-by":"crossref","DOI":"10.1016\/j.nut.2022.111847","article-title":"Effects of time-restricted feeding (16\/8) combined with a low-sugar diet on the management of non-alcoholic fatty liver disease: a randomized controlled trial","volume":"105","author":"Kord-Varkaneh","year":"2023","journal-title":"Nutrition"},{"key":"10.1016\/j.obpill.2025.100164_bib101","doi-asserted-by":"crossref","DOI":"10.1016\/j.nut.2023.111982","article-title":"Macronutrient composition and its effect on body composition changes during weight loss therapy in patients with non-alcoholic fatty liver disease: secondary analysis of a randomized controlled trial","volume":"110","author":"Lindqvist","year":"2023","journal-title":"Nutrition"},{"issue":"3","key":"10.1016\/j.obpill.2025.100164_bib102","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhepr.2021.100256","article-title":"Treatment of NAFLD with intermittent calorie restriction or low-carb high-fat diet - a randomised controlled trial","volume":"3","author":"Holmer","year":"2021","journal-title":"JHEP reports"},{"issue":"1","key":"10.1016\/j.obpill.2025.100164_bib103","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-47763-8","article-title":"A\u00a0randomised controlled trial on the effectiveness and adherence of modified alternate-day calorie restriction in improving activity of non-alcoholic fatty liver disease","volume":"9","author":"Johari","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.obpill.2025.100164_bib104","doi-asserted-by":"crossref","DOI":"10.3389\/fnut.2022.948655","article-title":"Effects of the 5:2 intermittent fasting diet on non-alcoholic fatty liver disease: a randomized controlled trial","volume":"9","author":"Kord Varkaneh","year":"2022","journal-title":"Front Nutr"},{"issue":"1","key":"10.1016\/j.obpill.2025.100164_bib105","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.cmet.2022.12.001","article-title":"Effect of alternate day fasting combined with aerobic exercise on non-alcoholic fatty liver disease: a randomized controlled trial","volume":"35","author":"Ezpeleta","year":"2023","journal-title":"Cell Metab"},{"issue":"23","key":"10.1016\/j.obpill.2025.100164_bib106","doi-asserted-by":"crossref","DOI":"10.3390\/nu15234870","article-title":"Time-restricted fasting improves liver steatosis in non-alcoholic fatty liver disease-A single blinded crossover trial","volume":"15","author":"Feehan","year":"2023","journal-title":"Nutrients"},{"issue":"3","key":"10.1016\/j.obpill.2025.100164_bib107","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.3513","article-title":"Effects of time-restricted eating on nonalcoholic fatty liver disease: the TREATY-FLD randomized clinical trial","volume":"6","author":"Wei","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"8","key":"10.1016\/j.obpill.2025.100164_bib108","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1016\/j.cgh.2018.05.023","article-title":"Evaluations of lifestyle, dietary, and pharmacologic treatments for pediatric nonalcoholic fatty liver disease: a systematic review","volume":"17","author":"Mann","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"3","key":"10.1016\/j.obpill.2025.100164_bib109","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1002\/cld.1022","article-title":"Lifestyle intervention as the primary treatment for pediatric nonalcoholic fatty liver disease","volume":"17","author":"Kohut","year":"2021","journal-title":"Clinical Liver Disease"},{"issue":"8","key":"10.1016\/j.obpill.2025.100164_bib110","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1139\/apnm-2012-0503","article-title":"Role of physical activity in the treatment of nonalcoholic fatty liver disease in children and adolescents","volume":"38","author":"Deldin","year":"2013","journal-title":"Appl Physiol Nutr Metab"},{"issue":"6","key":"10.1016\/j.obpill.2025.100164_bib111","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1002\/hep.28392","article-title":"Diet, weight loss, and liver health in nonalcoholic fatty liver disease: pathophysiology, evidence, and practice","volume":"63","author":"Marchesini","year":"2016","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.obpill.2025.100164_bib112","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1002\/hep.23719","article-title":"Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis: the central role of nontriglyceride fatty acid metabolites","volume":"52","author":"Neuschwander-Tetri","year":"2010","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.obpill.2025.100164_bib113","doi-asserted-by":"crossref","first-page":"89","DOI":"10.3727\/105221617X15124844266408","article-title":"The effects of physical exercise on fatty liver disease","volume":"18","author":"Van Der Windt","year":"2018","journal-title":"Gene Expr"},{"issue":"7","key":"10.1016\/j.obpill.2025.100164_bib114","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1080\/17461391.2019.1571114","article-title":"Mechanisms of beneficial effects of exercise training on non\u2010alcoholic fatty liver disease (NAFLD): roles of oxidative stress and inflammation","volume":"19","author":"Farzanegi","year":"2019","journal-title":"Eur J Sport Sci"},{"issue":"9","key":"10.1016\/j.obpill.2025.100164_bib115","doi-asserted-by":"crossref","DOI":"10.3390\/nu13093135","article-title":"Positive effects of exercise intervention without weight loss and dietary changes in NAFLD-related clinical parameters: a systematic review and meta-analysis","volume":"13","author":"Babu","year":"2021","journal-title":"Nutrients"},{"issue":"10","key":"10.1016\/j.obpill.2025.100164_bib116","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1016\/j.jand.2014.07.005","article-title":"Diet or exercise interventions vs combined behavioral weight management programs: a systematic review and meta-analysis of direct comparisons","volume":"114","author":"Johns","year":"2014","journal-title":"J\u00a0Acad Nutr Diet"},{"issue":"2","key":"10.1016\/j.obpill.2025.100164_bib117","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1111\/liv.15769","article-title":"Exercise training improves serum biomarkers of liver fibroinflammation in patients with metabolic dysfunction-associated steatohepatitis","volume":"44","author":"Harris","year":"2024","journal-title":"Liver Int"},{"issue":"2","key":"10.1016\/j.obpill.2025.100164_bib118","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1038\/oby.2009.274","article-title":"A\u00a012\u2010Week aerobic exercise program reduces hepatic fat accumulation and insulin resistance in obese, hispanic adolescents","volume":"18","author":"Van Der Heijden","year":"2009","journal-title":"Obesity"},{"issue":"11","key":"10.1016\/j.obpill.2025.100164_bib119","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1249\/MSS.0b013e3181df16d9","article-title":"Strength exercise improves muscle mass and hepatic insulin sensitivity in obese youth","volume":"42","author":"Van Der Heijden","year":"2010","journal-title":"Med Sci Sports Exerc"},{"issue":"9","key":"10.1016\/j.obpill.2025.100164_bib120","doi-asserted-by":"crossref","DOI":"10.3390\/nu12092864","article-title":"Effects of dietary and lifestyle interventions on liver, clinical and metabolic parameters in children and adolescents with non-alcoholic fatty liver disease: a systematic review","volume":"12","author":"Katsagoni","year":"2020","journal-title":"Nutrients"},{"issue":"4","key":"10.1016\/j.obpill.2025.100164_bib121","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1089\/chi.2017.0027","article-title":"The effects of exercise on abdominal fat and liver enzymes in pediatric obesity: a systematic review and meta-analysis","volume":"13","author":"Gonz\u00e1lez-Ruiz","year":"2017","journal-title":"Child Obes"},{"issue":"2","key":"10.1016\/j.obpill.2025.100164_bib122","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.pcad.2018.01.013","article-title":"Evidence-based exercise recommendations to reduce hepatic fat content in youth- a systematic review and meta-analysis","volume":"61","author":"Medrano","year":"2018","journal-title":"Prog Cardiovasc Dis"},{"issue":"3","key":"10.1016\/j.obpill.2025.100164_bib123","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1002\/jpr3.12072","article-title":"Patient perspective on exercise practices, preferences, and barriers in pediatric nonalcoholic fatty liver disease: a multicenter survey","volume":"5","author":"Yu","year":"2024","journal-title":"JPGN rep"},{"issue":"8","key":"10.1016\/j.obpill.2025.100164_bib124","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/1479-5868-8-78","article-title":"How many steps\/day are enough? for children and adolescents","volume":"28","author":"Tudor-Locke","year":"2011","journal-title":"Int J Behav Nutr Phys Act"},{"key":"10.1016\/j.obpill.2025.100164_bib125","article-title":"MASH clinical trials and drugs pipeline: an impending tsunami","author":"Noureddin","year":"2024","journal-title":"Hepatology"},{"issue":"8","key":"10.1016\/j.obpill.2025.100164_bib126","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1016\/j.cgh.2023.03.041","article-title":"Clinical trial landscape in NASH","volume":"21","author":"Harrison","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.obpill.2025.100164_bib127","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1159\/000539371","article-title":"EASL-EASD-EASO clinical practice guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)","volume":"17","year":"2024","journal-title":"Obes Facts"},{"issue":"3","key":"10.1016\/j.obpill.2025.100164_bib128","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.jhep.2024.04.031","article-title":"EASL\u2013EASD\u2013EASO clinical practice guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)","volume":"81","author":"Tacke","year":"2024","journal-title":"J\u00a0Hepatol"},{"issue":"6","key":"10.1016\/j.obpill.2025.100164_bib129","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMoa2309000","article-title":"A\u00a0phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis","volume":"390","author":"Harrison","year":"2024","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.obpill.2025.100164_bib130","doi-asserted-by":"crossref","DOI":"10.1038\/s44355-024-00004-w","article-title":"Resmetirom and GLP-1 agonists for MASH: complementary rather than exclusive","volume":"1","author":"Zhou","year":"2024","journal-title":"npj Gut Liver"},{"issue":"4","key":"10.1016\/j.obpill.2025.100164_bib131","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1002\/hep.24767","article-title":"The TONIC trial: a step forward in treating pediatric nonalcoholic fatty liver disease","volume":"55","author":"Groszmann","year":"2012","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.obpill.2025.100164_bib132","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1002\/hep.24767","article-title":"The TONIC trial: a step forward in treating pediatric nonalcoholic fatty liver disease","volume":"55","author":"Alkhouri","year":"2012","journal-title":"Hepatology"},{"issue":"9","key":"10.1016\/j.obpill.2025.100164_bib133","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.1016\/j.cgh.2021.07.020","article-title":"Obeticholic acid impact on quality of life in patients with nonalcoholic steatohepatitis: REGENERATE 18-month interim analysis","volume":"20","author":"Younossi","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"S2","key":"10.1016\/j.obpill.2025.100164_bib134","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1007\/s12072-024-10698-y","article-title":"Review of current and new drugs for the treatment of metabolic-associated fatty liver disease","volume":"18","author":"Gish","year":"2024","journal-title":"Hepatol Int"},{"key":"10.1016\/j.obpill.2025.100164_bib135","article-title":"Obesity management for the hepatologist\u2014what to do, how to do it and why?","author":"Watt","year":"2023","journal-title":"Hepatology"},{"issue":"12","key":"10.1016\/j.obpill.2025.100164_bib136","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","article-title":"A\u00a0placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis","volume":"384","author":"Newsome","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"11\u201312","key":"10.1016\/j.obpill.2025.100164_bib137","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1111\/apt.18331","article-title":"Semaglutide 2.4 mg in participants with metabolic dysfunction-associated steatohepatitis: baseline characteristics and design of the phase 3 ESSENCE trial","volume":"60","author":"Newsome","year":"2024","journal-title":"Aliment Pharmacol Therapeut"},{"issue":"24","key":"10.1016\/j.obpill.2025.100164_bib138","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1056\/NEJMoa2208601","article-title":"Once-weekly semaglutide in adolescents with obesity","volume":"387","author":"Weghuber","year":"2022","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.obpill.2025.100164_bib139","article-title":"Liraglutide for children 6 to","author":"Fox","year":"2024","journal-title":"N\u00a0Engl J Med"},{"issue":"S1","key":"10.1016\/j.obpill.2025.100164_bib140","first-page":"S1","article-title":"Glp-1 receptor agonists have a potential to improve disease activity in pediatric metabolic dysfunction-associated steatotic liver disease","volume":"80","author":"Tou","year":"2024","journal-title":"Hepatology"},{"key":"10.1016\/j.obpill.2025.100164_bib141","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.769069","article-title":"Efficacy and safety of GLP-1 receptor agonists in patients with type 2 diabetes mellitus and non-alcoholic fatty liver disease: a systematic review and meta-analysis","volume":"12","author":"Zhu","year":"2021","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.obpill.2025.100164_bib142","unstructured":"Sorli C, Harashima S, Tsoukas GM, et\u00a0al. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial."},{"issue":"11","key":"10.1016\/j.obpill.2025.100164_bib143","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.obpill.2025.100164_bib144","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1053\/j.gastro.2007.03.054","article-title":"Biology of incretins: GLP-1 and GIP","volume":"132","author":"Baggio","year":"2007","journal-title":"Gastroenterology"},{"issue":"8","key":"10.1016\/j.obpill.2025.100164_bib145","doi-asserted-by":"crossref","first-page":"e2695","DOI":"10.1210\/clinem\/dgaa285","article-title":"Obesity, polycystic ovary syndrome, and infertility: a new avenue for GLP-1 receptor agonists","volume":"105","author":"Cena","year":"2020","journal-title":"J\u00a0Clin Endocrinol Metabol"},{"issue":"20","key":"10.1016\/j.obpill.2025.100164_bib146","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1056\/NEJMp2400978","article-title":"Fair allocation of GLP-1 and dual GLP-1-GIP receptor agonists","volume":"390","author":"Emanuel","year":"2024","journal-title":"N\u00a0Engl J Med"},{"issue":"10403","key":"10.1016\/j.obpill.2025.100164_bib147","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/S0140-6736(23)01185-6","article-title":"Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"402","author":"Knop","year":"2023","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.obpill.2025.100164_bib148","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Jastreboff","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.obpill.2025.100164_bib149","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1056\/NEJMoa2401943","article-title":"Tirzepatide for metabolic Dysfunction\u2013Associated steatohepatitis with liver fibrosis","volume":"391","author":"Loomba","year":"2024","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.obpill.2025.100164_bib150","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa2401755","article-title":"A\u00a0phase 2 randomized trial of survodutide in MASH and fibrosis","volume":"391","author":"Sanyal","year":"2024","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.obpill.2025.100164_bib151","article-title":"Effect of pemvidutide, a GLP-1\/glucagon dual receptor agonist, on MASLD: a randomized, double-blind, placebo-controlled study","author":"Harrison","year":"2024","journal-title":"J\u00a0Hepatol"},{"issue":"6","key":"10.1016\/j.obpill.2025.100164_bib152","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMoa2309000","article-title":"A\u00a0phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis","volume":"390","author":"Harrison","year":"2024","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.obpill.2025.100164_bib153","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1177\/0009922814542481","article-title":"Topiramate for weight reduction in adolescents with severe obesity","volume":"54","author":"Fox","year":"2015","journal-title":"Clin Pediatr"},{"key":"10.1016\/j.obpill.2025.100164_bib154","article-title":"Topiramate treatment of pediatric metabolic dysfunction-associated steatotic liver disease: a descriptive cohort study","author":"Kohut","year":"2024","journal-title":"JPEN - J Parenter Enter Nutr"},{"issue":"9","key":"10.1016\/j.obpill.2025.100164_bib155","doi-asserted-by":"crossref","DOI":"10.1001\/jama.2024.11809","article-title":"Obesity in adolescents","volume":"332","author":"Kelly","year":"2024","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.obpill.2025.100164_bib156","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200014","article-title":"Phentermine\/topiramate for the treatment of adolescent obesity","volume":"1","author":"Kelly","year":"2022","journal-title":"NEJM Evid"},{"issue":"5","key":"10.1016\/j.obpill.2025.100164_bib157","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1002\/oby.20309","article-title":"A\u00a0randomized, phase 3 trial of naltrexone SR\/bupropion SR on weight and obesity-related risk factors (COR-II)","volume":"21","author":"Apovian","year":"2013","journal-title":"Obesity"},{"issue":"12","key":"10.1016\/j.obpill.2025.100164_bib158","doi-asserted-by":"crossref","first-page":"4022","DOI":"10.2337\/dc13-0234","article-title":"Effects of naltrexone sustained-release\/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes","volume":"36","author":"Hollander","year":"2013","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.obpill.2025.100164_bib159","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.clinthera.2020.10.010","article-title":"Naltrexone + bupropion combination for the treatment of binge-eating disorder with obesity: a randomized, controlled pilot study","volume":"43","author":"Grilo","year":"2021","journal-title":"Clin Ther"},{"issue":"4","key":"10.1016\/j.obpill.2025.100164_bib160","doi-asserted-by":"crossref","first-page":"400","DOI":"10.4088\/JCP.12m08071","article-title":"Bupropion for overweight women with binge-eating disorder: a randomized, double-blind, placebo-controlled trial","volume":"74","author":"White","year":"2013","journal-title":"J\u00a0Clin Psychiatr"},{"issue":"20","key":"10.1016\/j.obpill.2025.100164_bib161","doi-asserted-by":"crossref","DOI":"10.1001\/jama.2023.19897","article-title":"Obesity management in adults","volume":"330","author":"Elmaleh-Sachs","year":"2023","journal-title":"JAMA"},{"issue":"22","key":"10.1016\/j.obpill.2025.100164_bib162","doi-asserted-by":"crossref","DOI":"10.1001\/jama.2016.7602","article-title":"Association of pharmacological treatments for obesity with weight loss and adverse events","volume":"315","author":"Khera","year":"2016","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.obpill.2025.100164_bib163","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1001\/jamapsychiatry.2014.2162","article-title":"Efficacy and safety of lisdexamfetamine for treatment of adults with moderate to severe binge-eating disorder: a randomized clinical trial","volume":"72","author":"McElroy","year":"2015","journal-title":"JAMA Psychiatr"},{"issue":"3","key":"10.1016\/j.obpill.2025.100164_bib164","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/s40265-021-01470-9","article-title":"Setmelanotide: first approval","volume":"81","author":"Markham","year":"2021","journal-title":"Drugs"},{"issue":"12","key":"10.1016\/j.obpill.2025.100164_bib165","first-page":"960","article-title":"Efficacy and safety of setmelanotide, an MC4R agonist, in individuals with severe obesity due to LEPR or POMC deficiency: single-arm, open-label, multicentre, phase 3 trials","volume":"8","author":"Cl\u00e9ment","year":"2020","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.obpill.2025.100164_bib166","article-title":"Beneficial effects of setmelanotide in a 5-year-old boy with POMC deficiency and on his caregivers","volume":"1","author":"Dubern","year":"2023","journal-title":"JCEM Case Rep"},{"issue":"5","key":"10.1016\/j.obpill.2025.100164_bib167","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1159\/000348541","article-title":"Rapid improvement of hepatic steatosis after initiation of leptin substitution in a leptin-deficient girl","volume":"79","author":"von Schnurbein","year":"2013","journal-title":"Hormone Res P\u00e6diatrics :"},{"key":"10.1016\/j.obpill.2025.100164_bib168","article-title":"The complicated clinical course in a case of atypical lipodystrophy after development of neutralizing antibody to metreleptin: treatment with setmelanotide","volume":"2020","author":"Akinci","year":"2020","journal-title":"Endocrinolo Diabetes Metabol Case Rep"},{"key":"10.1016\/j.obpill.2025.100164_bib169","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.metabol.2018.11.014","article-title":"Obesity and nonalcoholic fatty liver disease: from pathophysiology to therapeutics","volume":"92","author":"Polyzos","year":"2019","journal-title":"Metabolism"},{"issue":"5","key":"10.1016\/j.obpill.2025.100164_bib170","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.13172","article-title":"GLP-1 receptor agonist discontinuation among patients with obesity and\/or type 2 diabetes","volume":"7","author":"Do","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"8","key":"10.1016\/j.obpill.2025.100164_bib171","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1111\/dom.14725","article-title":"Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension","volume":"24","author":"Wilding","year":"2022","journal-title":"Diabetes Obes Metabol"},{"issue":"14","key":"10.1016\/j.obpill.2025.100164_bib172","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1001\/jama.2021.3224","article-title":"Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial","volume":"325","author":"Rubino","year":"2021","journal-title":"JAMA"},{"issue":"3\u20134","key":"10.1016\/j.obpill.2025.100164_bib173","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1900\/RDS.2014.11.202","article-title":"Adverse effects of GLP-1 receptor agonists","volume":"11","author":"Filippatos","year":"2014","journal-title":"Rev Diabet Stud"},{"key":"10.1016\/j.obpill.2025.100164_bib174","unstructured":"Abai B, author. Compare and contrast the glucagon-like peptide-1 receptor agonists (GLP1RAs). Treasure Island (FL) : StatPearls Publishing."},{"issue":"24","key":"10.1016\/j.obpill.2025.100164_bib175","doi-asserted-by":"crossref","first-page":"3200","DOI":"10.1016\/j.jacc.2018.09.020","volume":"72","author":"Das","year":"2018","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"3","key":"10.1016\/j.obpill.2025.100164_bib176","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1210\/en.2011-1864","article-title":"GLP-1 receptor agonists and the thyroid: C-cell effects in mice are mediated via the GLP-1 receptor and not associated with RET activation","volume":"153","author":"Madsen","year":"2012","journal-title":"Endocrinology"},{"key":"10.1016\/j.obpill.2025.100164_bib177","article-title":"Glucagon-like peptide-1 receptor agonist use in pregnancy: a review","author":"Drummond","year":"2024","journal-title":"Am J Obstet Gynecol"},{"issue":"1","key":"10.1016\/j.obpill.2025.100164_bib178","doi-asserted-by":"crossref","DOI":"10.1136\/bmjdrc-2019-000728","article-title":"Effect of incretin-based therapies on cancers of digestive system among 101 595 patients with type 2 diabetes mellitus: a systematic review and network meta-analysis combining 84 trials with a median duration of 30 weeks","volume":"7","author":"Chai","year":"2019","journal-title":"BMJ Open Diabetes Res Care"},{"issue":"4","key":"10.1016\/j.obpill.2025.100164_bib179","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1111\/dom.13924","article-title":"Incretin-based glucose-lowering medications and the risk of acute pancreatitis and malignancies: a meta-analysis based on cardiovascular outcomes trials","volume":"22","author":"Abd El Aziz","year":"2020","journal-title":"Diabetes Obes Metabol"},{"issue":"4","key":"10.1016\/j.obpill.2025.100164_bib180","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1111\/dom.13597","article-title":"Exenatide use and incidence of pancreatic and thyroid cancer: a retrospective cohort study","volume":"21","author":"Liang","year":"2019","journal-title":"Diabetes Obes Metabol"},{"issue":"2","key":"10.1016\/j.obpill.2025.100164_bib181","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1002\/oby.23622","article-title":"Real-world weight-loss effectiveness of glucagon-like peptide-1 agonists among patients with type 2 diabetes: a retrospective cohort study","volume":"31","author":"White","year":"2023","journal-title":"Obesity"},{"issue":"1","key":"10.1016\/j.obpill.2025.100164_bib182","doi-asserted-by":"crossref","DOI":"10.3390\/ijerph17010207","article-title":"Long-term effectiveness of liraglutide for weight management and glycemic control in type 2 diabetes","volume":"17","author":"Mirabelli","year":"2019","journal-title":"Int J Environ Res Publ Health"},{"key":"10.1016\/j.obpill.2025.100164_bib183","article-title":"Comparison of the efficacy of glucagon-like peptide-1 receptor agonists in patients with metabolic associated fatty liver disease: updated systematic review and meta-analysis","volume":"11","author":"Dai","year":"2020","journal-title":"Front Endocrinol"},{"issue":"8","key":"10.1016\/j.obpill.2025.100164_bib184","doi-asserted-by":"crossref","DOI":"10.1002\/dmrr.3061","article-title":"No pancreatic safety concern following glucagon-like peptide-1 receptor agonist therapies: a pooled analysis of cardiovascular outcome trials","volume":"34","author":"Liu","year":"2018","journal-title":"Diabetes\/metabolism Res Rev"},{"issue":"6","key":"10.1016\/j.obpill.2025.100164_bib185","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1111\/dom.15524","article-title":"The role of glucagon-like peptide-1 receptor agonists in metabolic dysfunction-associated steatohepatitis","volume":"26","author":"Abdelmalek","year":"2024","journal-title":"Diabetes Obes Metabol"},{"issue":"2","key":"10.1016\/j.obpill.2025.100164_bib186","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1080\/07315724.2014.901196","article-title":"Comparison of prevalence of inadequate nutrient intake based on body weight status of adults in the United States: an analysis of NHANES 2001-2008","volume":"34","author":"Agarwal","year":"2015","journal-title":"J\u00a0Am Coll Nutr"},{"issue":"5","key":"10.1016\/j.obpill.2025.100164_bib187","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1038\/sj.ijo.0803483","article-title":"Changes in fat-free mass during significant weight loss: a systematic review","volume":"31","author":"Chaston","year":"2007","journal-title":"Int J Obes"},{"issue":"11","key":"10.1016\/j.obpill.2025.100164_bib188","article-title":"Fundamental body composition principles provide context for fat-free and skeletal muscle loss with GLP-1 RA treatments","volume":"8","author":"Tinsley","year":"2024","journal-title":"J\u00a0Endocrine Soci"},{"issue":"1","key":"10.1016\/j.obpill.2025.100164_bib189","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1001\/jama.2024.6586","article-title":"Is weight loss-induced muscle mass loss clinically relevant?","volume":"332","author":"Conte","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.obpill.2025.100164_bib190","article-title":"GLP-1 receptor agonists: a novel pharmacotherapy for binge eating (binge eating disorder and bulimia nervosa)? A systematic review","volume":"35","author":"Aoun","year":"2024","journal-title":"J\u00a0Clinic Translat Endocrinol"},{"issue":"2","key":"10.1016\/j.obpill.2025.100164_bib191","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1002\/eat.24109","article-title":"Use of glucagon-like peptide-1 receptor agonists in eating disorder populations","volume":"57","author":"Bartel","year":"2024","journal-title":"Int J Eat Disord"},{"issue":"2","key":"10.1016\/j.obpill.2025.100164_bib192","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1053\/j.gastro.2024.03.015","article-title":"Increased risk of aspiration pneumonia associated with endoscopic procedures among patients with glucagon-like peptide 1 receptor agonist use","volume":"167","author":"Yeo","year":"2024","journal-title":"Gastroenterology"},{"key":"10.1016\/j.obpill.2025.100164_bib193","article-title":"Effects of glucagon-like peptide-1 receptor agonists on upper gastrointestinal endoscopy: a meta-analysis","author":"Facciorusso","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.obpill.2025.100164_bib194","article-title":"Do glucagon-like peptide receptor agonists cause postendoscopic aspiration pneumonia?","author":"Hartmann","year":"2024","journal-title":"Gastroenterology"},{"key":"10.1016\/j.obpill.2025.100164_bib195","article-title":"Multisociety clinical practice guidance for the safe use of glucagon-like peptide-1 receptor agonists in the perioperative period","author":"Kindel","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"3","key":"10.1016\/j.obpill.2025.100164_bib196","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.soard.2021.11.015","article-title":"ASMBS position statement on the impact of metabolic and bariatric surgery on nonalcoholic steatohepatitis","volume":"18","author":"Mazzini","year":"2022","journal-title":"Surg Obes Relat Dis"},{"issue":"11","key":"10.1016\/j.obpill.2025.100164_bib197","doi-asserted-by":"crossref","first-page":"2274","DOI":"10.1016\/j.cgh.2020.08.061","article-title":"Change in MRI-PDFF and histologic response in patients with nonalcoholic steatohepatitis: a systematic review and meta-analysis","volume":"19","author":"Stine","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"3","key":"10.1016\/j.obpill.2025.100164_bib198","first-page":"561","article-title":"Bariatric intervention improves metabolic dysfunction-associated steatohepatitis in patients with obesity: a systematic review and meta-analysis","volume":"30","author":"Hwang","year":"2024","journal-title":"CMH"},{"issue":"1","key":"10.1016\/j.obpill.2025.100164_bib199","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s13679-023-00540-1","article-title":"Metabolic and bariatric surgery in children: current practices and outcomes","volume":"13","author":"Shah","year":"2024","journal-title":"Curr Obesity Rep"},{"issue":"7","key":"10.1016\/j.obpill.2025.100164_bib200","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/j.soard.2018.03.019","article-title":"ASMBS pediatric metabolic and bariatric surgery guidelines","volume":"14","author":"Pratt","year":"2018","journal-title":"Surg Obes Relat Dis"},{"issue":"1","key":"10.1016\/j.obpill.2025.100164_bib201","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1053\/j.gastro.2018.09.021","article-title":"Factors associated with histologic response in adult patients with nonalcoholic steatohepatitis","volume":"156","author":"Loomba","year":"2019","journal-title":"Gastroenterology"},{"issue":"12","key":"10.1016\/j.obpill.2025.100164_bib202","doi-asserted-by":"crossref","first-page":"4181","DOI":"10.1007\/s11695-023-06930-7","article-title":"Obesity, type 2 diabetes, NASH, and the promising role of bariatric surgery: insights from the BRAVES trial","volume":"33","author":"Talha","year":"2023","journal-title":"Obes Surg"},{"issue":"8","key":"10.1016\/j.obpill.2025.100164_bib203","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1001\/jama.2024.0318","article-title":"Long-term outcomes of medical management vs bariatric surgery in type 2 diabetes","volume":"331","author":"Courcoulas","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.obpill.2025.100164_bib204","article-title":"Recompensation in MASLD-related cirrhosis via metabolic bariatric surgery","author":"Feng","year":"2024","journal-title":"Trends Endocrinol Metabol"},{"issue":"11","key":"10.1016\/j.obpill.2025.100164_bib205","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1016\/j.jpedsurg.2007.08.010","article-title":"Teen-longitudinal assessment of bariatric surgery: methodological features of the first prospective multicenter study of adolescent bariatric surgery","volume":"42","author":"Inge","year":"2007","journal-title":"J\u00a0Pediatr Surg"},{"issue":"4","key":"10.1016\/j.obpill.2025.100164_bib206","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1097\/XCS.0000000000000325","article-title":"Long-term outcomes after adolescent bariatric surgery","volume":"235","author":"de la Cruz-Mu\u00f1oz","year":"2022","journal-title":"J\u00a0Am Coll Surg"},{"issue":"10","key":"10.1016\/j.obpill.2025.100164_bib207","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1016\/j.soard.2016.06.004","article-title":"PNPLA3 p.I148M variant is associated with greater reduction of liver fat content after bariatric surgery","volume":"12","author":"Krawczyk","year":"2016","journal-title":"Surg Obes Relat Dis"},{"issue":"2","key":"10.1016\/j.obpill.2025.100164_bib208","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s13668-022-00400-9","article-title":"Nutritional deficiencies before and after bariatric surgery: prevention and treatment","volume":"11","author":"Argyrakopoulou","year":"2022","journal-title":"Curr Nutrit Rep"},{"issue":"8","key":"10.1016\/j.obpill.2025.100164_bib209","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.29178","article-title":"Cost-effectiveness of pharmacotherapy for the treatment of obesity in adolescents","volume":"6","author":"Lim","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"10","key":"10.1016\/j.obpill.2025.100164_bib210","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.36400","article-title":"Cost-effectiveness of antiobesity drugs for adolescents with severe obesity","volume":"6","author":"Mital","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"4","key":"10.1016\/j.obpill.2025.100164_bib211","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.jhep.2017.05.016","article-title":"Treatment of NAFLD with diet, physical activity and exercise","volume":"67","author":"Romero-G\u00f3mez","year":"2017","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.obpill.2025.100164_bib212","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2023.1316284","article-title":"MASLD treatment-a shift in the paradigm is imminent","volume":"10","author":"Machado","year":"2023","journal-title":"Front Med"},{"issue":"3","key":"10.1016\/j.obpill.2025.100164_bib213","first-page":"223","article-title":"Primary health care access, continuity, and cost among pediatric patients with obesity hypertension","volume":"101","author":"Jerrell","year":"2009","journal-title":"J\u00a0Natl Med Assoc"},{"issue":"2","key":"10.1016\/j.obpill.2025.100164_bib214","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.gtc.2023.02.003","article-title":"Disparities in access and quality of obesity care","volume":"52","author":"Washington","year":"2023","journal-title":"Gastroenterol Clin N Am"}],"container-title":["Obesity Pillars"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667368125000087?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667368125000087?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T23:22:20Z","timestamp":1762644140000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2667368125000087"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":214,"alternative-id":["S2667368125000087"],"URL":"https:\/\/doi.org\/10.1016\/j.obpill.2025.100164","relation":{},"ISSN":["2667-3681"],"issn-type":[{"value":"2667-3681","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Metabolic dysfunction-associated steatotic liver disease (MASLD) in children with obesity: An Obesity Medicine Association (OMA) and expert joint perspective 2025","name":"articletitle","label":"Article Title"},{"value":"Obesity Pillars","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.obpill.2025.100164","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc. on behalf of Obesity Medicine Association.","name":"copyright","label":"Copyright"}],"article-number":"100164"}}